Sold as Flumadine. Every FDA application for this active ingredient: 2 branded and 3 generic.
As of Nov 16, 2026, FDA lists 5 applications for Rimantadine Hydrochloride (sold as Flumadine), first approved Sep 17, 1993, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Rimantadine HCl | Part D | $112K | -11% | 178 |
| Sep 17, 1993 | FlumadineNDA 19649 · New molecular entity | Sun Pharm Inds Inc | 10 | Discontinued |
| Sep 17, 1993 | FlumadineNDA 19650 · New dosage form | Forest Labs | 4 | Discontinued |
| Nov 2, 2001 | Rimantadine HydrochlorideANDA 75916 | Impax Labs Inc | 0 | Discontinued |
| Aug 30, 2002 | Rimantadine HydrochlorideANDA 76132 | Impax Labs | 1 | Marketed |
| Jan 14, 2003 | Rimantadine HydrochlorideANDA 76375 | Chartwell Rx | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA